In vitro drug resistance in 182 children with ETV6/RUNX1+ or ETV6/RUNX1- precursor B-ALL excluding patients with high hyperdiploidy (> 51), t(9;22), t(1;19), and 11q23 rearrangement
. | ETV6/RUNX1+ . | ETV6/RUNX1- . | . |
|---|---|---|---|
| Drug . | Median (25th-75th) . | Median (25th-75th) . | P . |
| Doxorubicin | 32 (16-44) | 44 (27-57) | .001 |
| Etoposide | 35 (22-54) | 55 (33-73) | .001 |
| Amsacrine | 29 (17-45) | 34 (20-52) | .093 |
| Dexamethasone | 49 (31-67) | 60 (42-78) | .051 |
| Cytarabine | 63 (52-75) | 63 (45-75) | .51 |
| Prednisolone | 52 (31-73) | 56 (38-72) | .18 |
| Vincristine | 53 (41-67) | 53 (41-76) | .56 |
| 6-thioguanine | 42 (24-61) | 45 (29-62) | .30 |
| 4-HC | 20 (12-48) | 29 (15-44) | .53 |
. | ETV6/RUNX1+ . | ETV6/RUNX1- . | . |
|---|---|---|---|
| Drug . | Median (25th-75th) . | Median (25th-75th) . | P . |
| Doxorubicin | 32 (16-44) | 44 (27-57) | .001 |
| Etoposide | 35 (22-54) | 55 (33-73) | .001 |
| Amsacrine | 29 (17-45) | 34 (20-52) | .093 |
| Dexamethasone | 49 (31-67) | 60 (42-78) | .051 |
| Cytarabine | 63 (52-75) | 63 (45-75) | .51 |
| Prednisolone | 52 (31-73) | 56 (38-72) | .18 |
| Vincristine | 53 (41-67) | 53 (41-76) | .56 |
| 6-thioguanine | 42 (24-61) | 45 (29-62) | .30 |
| 4-HC | 20 (12-48) | 29 (15-44) | .53 |
The concentrations of the drugs used are denoted in Table 1. Children with high hyperdiploidy (n = 81; data available in 78% of the cases), t(9;22) (n = 5; data available in 85% of the cases), t(1;19) (n = 6; data available in 50% of the cases), 11q23 rearrangement (n = 4; data available in 50% of the cases) were excluded from the cohort of 275 patients. Some patients had more than one chromosomal aberration.
All the values represent the percentage of surviving cells compared with control wells, and are shown as median and 25th to 75th percentile. P values were determined by the Mann-Whitney U test.